BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Mesoblast readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Mesoblast's drugs run\, from Clin
 icalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06325566-10810@assetmemo.bio
DTSTAMP:20261121T004552Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:rexlemestrocel-L: Phase 3 readout est. (NCT06325566)
DESCRIPTION:rexlemestrocel-L\, phase 3\, Chronic Low Back Pain.\nStudy: Eff
 icacy and Safety of Rexlemestrocel-L Combined With HA* in Participants Wit
 h Moderate to Severe Chronic Low Back Pain\nEstimated primary completion: 
 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rexlemestr
 ocel-l#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06325566
URL:https://assetmemo.bio/drug/rexlemestrocel-l#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07568535-87@assetmemo.bio
DTSTAMP:20261121T004552Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Ryoncil (remestemcel-L): Phase 3 readout est. (NCT07568535)
DESCRIPTION:Ryoncil (remestemcel-L)\, phase 3\, Graft-versus-Host Disease.\
 nStudy: A Randomized\, Double-Blind\, Placebo-Controlled\, Multicenter Pha
 se III Trial of Remestemcel-L-rknd Added to Ruxolitinib for Grade III-IV S
 teroid-Refractory Acute Graft-Versus-Host Disease\nEstimated primary compl
 etion: 28 February 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/remestemcel-l#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07568535
URL:https://assetmemo.bio/drug/remestemcel-l#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
